PAPILLON trial: Amivantamab plus chemotherapy adds months of survival in rare lung cancer

Final results from the landmark PAPILLON trial, which changed the modular of attraction for a difficult-to-treat uncommon signifier of lung cancer, corroborate that amivantamab, erstwhile added to chemotherapy, provides durable objective payment and the longest median wide endurance reported to day for radical with the disease.